Newsletter Subject

➯ If you wait for FDA approval, it could be too late ... [Sep 29, 2024]

From

saveandincrease.com

Email Address

hello@e.saveandincrease.com

Sent On

Sun, Sep 29, 2024 05:24 PM

Email Preheader Text

Biotech can be one of the most rewarding sectors in the market. ? ? Biotech can be one of the mo

Biotech can be one of the most rewarding sectors in the market.   [logo](   Biotech can be one of the most rewarding sectors in the market. In fact, the list of 2024's best stocks is peppered with biotech names. Like Viking Therapeutics, up 210% this year alone. Or Arcutis Biotherapeutics, up 212% already in 2024. Janux Therapeutics is up 210% so far this year. [But there's only one problem …]( Unless you have a PhD … Or an inside source … Good luck picking biotech winners ahead of time. The FDA approval process is extremely difficult. It can cost billions of dollars … And last more than a decade. Even then, after multiple phases of trials, a drug can still be rejected. In fact, 9 in 10 drugs never get approval from the FDA. They die on the vine. And even for the ones who survive, it can be hard to get any information on the status of a drug … Or how close it is to approval. The FDA is notoriously opaque. [But for a special set of drug companies, all of that has changed.]( The FDA has started to quietly send out a signal. This signal means specific companies will get an expedited route to approval … And hands-on guidance from the FDA. For investors, there's something even more important going on here … Over 97% of the time the FDA sends out this signal … The company involved has seen its stock spike sometime in the following months. 74 out of 76 times since 2016. For an average gain of 117% in just eight months. And it has nothing to do with approval or rejection. Take Adaptimmune Therapeutics, for example. [Chart]( Shares were hovering around one dollar when the FDA sent out this quiet signal on Adaptimmune's new tumor drug. Within six months, the stock shot up 845% It took almost four more years before the drug was approved. [Chart]( Caladrius Biosciences' stock was going nowhere, stuck around $4 … Then it got this FDA signal. And shares jumped 119% — in two days. The drug in question wasn't approved for another five years … [Chart]( Ocugen received an FDA signal in December 2023. Its share price spiked 435% in just five months. The drug has yet to be given final approval. It's a simple trade. The FDA sends out this signal. And 97% of the time the company's stock price has gone up in the following months. And whether the drug was eventually approved or not had no effect … [Now, I believe one drug company is on the verge of getting this FDA signal.]( In fact, I think it could happen very soon … [That's why I just put together an important video with all the details on this incredible signal — and the stock market winners it's produced.]( Sincerely, Michael Robinson, Editor Disruptors & Dominators Robin Nichols, Editor at SAI [quote] Sometimes, colleagues of Sаvе And Increase share special оffers with us that we think our readers should be made aware of. Above is one such special орроrtunity that we believe deserves your attention. [quote] You are receiving this e-mail because you have expressed an interest in the Fіnаncіаl Education niche on one of our landing pages or sign-up forms.[.]( 11780 US Highway 1, Palm Beach Gardens, FL 33408-3080 Would you like to [edit your e-mail notification preferences or unsubscribe]( from our mailing list? Copyright © 2024 Weiss Ratings. All rights reserved. This email was sent to you by SаvеAndIncrease operator of Event Horizon LLC. 435 N Dupont Hwy, Dover, DE 19901, United States © 2024 Аll Rights Reserved. [.]( Got questions? We’ve got answers! Connect with our friendly support team to gеt the help you need, when you need it, simply send an email to support@saveandincrease.com. You’ll receive a response within 24 hours. [Privacy Policy]( | [Tеrms & Conditions]( [Unsubscribе]( [Logo](

Marketing emails from saveandincrease.com

View More
Sent On

18/10/2024

Sent On

18/10/2024

Sent On

17/10/2024

Sent On

17/10/2024

Sent On

17/10/2024

Sent On

16/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.